Last checked at 5 Dec 2022 07:00
OptiBiotix Health plc
("OptiBiotix” or the "Company”)
Issue of Equity - Subscription
Appointment of Joint Broker
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease, diabetes and skincare, announces that the Company has raised £500,000 through the issue of 3,125,000 new ordinary shares of 2 pence each in the Company ("Ordinary Shares") at a price of 16 pence per share (the "Subscription") handled by Peterhouse Capital Limited.
The net proceeds of the Subscription will be utilised to invest in the Company's direct-to-consumer ("D2C”) product model, in particular to drive sales growth across the business and build partnerships in the USA and for general working capital purposes.
Appointment of Joint Broker
Separately, the Company announces the appointment of Peterhouse Capital Limited as joint broker to the Company with immediate effect.
Admission
Application will be made to the London Stock Exchange to admit the 3,125,000 new Ordinary Shares to trading on AIM ("Admission”). Admission of the new Ordinary Shares is expected to occur on or around 9 December 2022. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.
Total Voting Rights
For the purpose of the Disclosure and Transparency Rules, following the issue of shares detailed above the enlarged issued share capital of the Company will comprise 91,190,661 ordinary shares of 2p each. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.
Stephen O'Hara, CEO of OptiBiotix, commented: "I am pleased with the interest shown from new and existing shareholders in this fundraise which will support further company growth. The funds will support an acceleration of our direct to consumer business, help expand our US partner network, and launch our second generation products into the market. These steps will help create shareholder value and support OptiBiotix's position as a leader in the microbiome field.”
This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.
For further information, please contact:
OptiBiotix Health plc | www.optibiotix.com | |
Neil Davidson, Chairman | Contact via Walbrook below | |
Stephen O'Hara, Chief Executive | ||
|
| |
Cairn Financial Advisers LLP (NOMAD) | Tel: 020 7213 0880 | |
Liam Murray / Jo Turner / Ludovico Lazzaretti | ||
| ||
Cenkos Securities plc (Joint Broker) | Tel: 020 7397 8900 | |
Callum Davidson | ||
Michael Johnson / Russell Kerr (Sales) | ||
| ||
Peterhouse Capital Limited (Joint Broker) | Tel: 020 7220 9797 | |
Duncan Vasey/ Lucy Williams
| ||
Walbrook PR Ltd | Mob: 07876 741 001 | |
Anna Dunphy | ||
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identiÞed by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reßect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.